sur Ottobock SE & Co. KGaA
Ottobock Achieves Record Results with Strong Growth in 2025
Ottobock SE & Co. KGaA reported substantial growth in 2025, registering a core revenue increase of 11.7% to EUR 1.6 billion. The company's underlying core EBITDA rose by nearly 30% to EUR 415 million, reflecting a margin of 26.0%. This impressive financial performance is attributed to successful strategy implementation, enhancing Ottobock's leadership in human bionics.
The company expanded its market influence by introducing innovative products like advanced knee joints and a revamped product line for arm and hand prosthetics. Strategic acquisitions in Belgium and Australia bolstered their Patient Care network. Across regions, EMEA saw growth of 12.7%, the Americas 9.5%, and APAC 7.4%.
Looking ahead, Ottobock forecasts continued robust growth in 2026, expecting a core business rise of 5.0-8.0% and further improvement in EBITDA margin. The company remains focused on long-term objectives, anticipating organic growth of 7.0-9.0% by 2029.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Ottobock SE & Co. KGaA